NCT01926587 2021-06-16
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Traws Pharma, Inc.
Phase 1/2 Completed
Clinical Trials
12 trialsNCT01928537 2020-06-30
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Traws Pharma, Inc.
Phase 3 Completed
NCT00854646 2018-01-10
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Traws Pharma, Inc.
Phase 1 Completed
NCT00856791 2017-07-21
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Traws Pharma, Inc.
Phase 2 Completed
NCT00854945 2017-06-26
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01167166 2017-06-26
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
Phase 1/2 Completed
NCT01807546 2017-06-26
Oral Rigosertib for Squamous Cell Carcinoma
Traws Pharma, Inc.
Phase 2 Completed
NCT00861783 2017-06-23
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Traws Pharma, Inc.
Phase 1 Completed
NCT01165905 2017-06-23
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01168011 2017-06-23
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Traws Pharma, Inc.
Phase 1 Completed
NCT01538563 2017-06-23
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
Traws Pharma, Inc.
Phase 1 Completed
NCT01360853 2016-08-04
ONTRAC
Traws Pharma, Inc.
Phase 3 Completed